Baker Avenue Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Baker Avenue Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-57,238	Closed	-$1.23M	–	778
2025 Q4	$1.23M	Sell	57,238 -4,825	-8%	-$102K	0.03%	246
2025 Q3	$1.2M	Buy	+62,063	New	+$1.11M	0.03%	241
2023 Q4	–	Sell	-46	Closed	-$5.58K	–	1331
2023 Q3	$5.58K	Hold	46	–	–	﹤0.01%	914
2023 Q2	$5.27K	Hold	46	–	–	﹤0.01%	845
2023 Q1	$6.34K	Hold	46	–	–	﹤0.01%	835
2022 Q4	$5.96K	Buy	+46	New	+$5.33K	﹤0.01%	788

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baker Avenue Asset Management's SRPT Position: Q1 2026 in Review

Baker Avenue Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 57,238 shares — an estimated $1.23M sold.

Baker Avenue Asset Management first reported a position in SRPT in Q4 2022 and held it in 6 quarters. The position peaked at $1.23M in Q4 2025. 345 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Baker Avenue Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
Baker Avenue Asset Management sold 57,238 Sarepta Therapeutics shares in Q1 2026, an estimated $1.23M.
Baker Avenue Asset Management first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 6 quarters.
Baker Avenue Asset Management's Sarepta Therapeutics position peaked at $1.23M in Q4 2025.
345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Baker Avenue Asset Management's 13F filing for Q1 2026, filed 12 May 2026.